@article{Zhao2021,
abstract = {Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at least one fully active nucleoside reverse transcriptase inhibitor (NRTI). Resistance testing to select NRTIs is not feasible in low- and middle-income countries due to cost and limited laboratory capacity. Evidence suggests that recycling tenofovir plus lamivudine or emtricitabine backbone with dolutegravir could provide an effective second-line option. This study aims to determine the virologic efficacy of tenofovir-lamivudine-dolutegravir (TLD) with and without a lead-in supplementary dose of dolutegravir (to counteract the inducing effect of efavirenz) in patients failing a first-line regimen of tenofovir-emtricitabine-efavirenz (TEE).},
author = {Zhao, Ying and Keene, Claire M and Griesel, Rulan and Sayed, Kaneez and Gcwabe, Zimasa and Jackson, Amanda and Ngwenya, Olina and Schutz, Charlotte and Goliath, Rene and Cassidy, Tali and Goemaere, Eric and Hill, Andrew and Maartens, Gary and Meintjes, Graeme A},
doi = {10.12688/wellcomeopenres.16597.1},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhao et al. - 2021 - AntiRetroviral Therapy In Second-line investigating tenofovir-lamivudine-dolutegravir (ARTIST) protocol for a rando.pdf:pdf},
issn = {2398-502X},
journal = {Wellcome Open Research},
keywords = {HIV,OA,Second-line,antiretroviral therapy,dolutegravir,fund{\_}ack,protocol,randomised controlled trial},
mendeley-tags = {OA,fund{\_}ack,protocol},
month = {feb},
pages = {33},
publisher = {F1000 Research Limited},
title = {{AntiRetroviral Therapy In Second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 1 approved]}},
url = {https://wellcomeopenresearch.org/articles/6-33/v1},
volume = {6},
year = {2021}
}

{"_id":"R7qYuheWoNL24dDhH","bibbaseid":"zhao-keene-griesel-sayed-gcwabe-jackson-ngwenya-schutz-etal-antiretroviraltherapyinsecondlineinvestigatingtenofovirlamivudinedolutegravirartistprotocolforarandomisedcontrolledtrialversion1peerreview1approved-2021","author_short":["Zhao, Y.","Keene, C. M","Griesel, R.","Sayed, K.","Gcwabe, Z.","Jackson, A.","Ngwenya, O.","Schutz, C.","Goliath, R.","Cassidy, T.","Goemaere, E.","Hill, A.","Maartens, G.","Meintjes, G. A"],"bibdata":{"bibtype":"article","type":"article","abstract":"Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at least one fully active nucleoside reverse transcriptase inhibitor (NRTI). Resistance testing to select NRTIs is not feasible in low- and middle-income countries due to cost and limited laboratory capacity. Evidence suggests that recycling tenofovir plus lamivudine or emtricitabine backbone with dolutegravir could provide an effective second-line option. This study aims to determine the virologic efficacy of tenofovir-lamivudine-dolutegravir (TLD) with and without a lead-in supplementary dose of dolutegravir (to counteract the inducing effect of efavirenz) in patients failing a first-line regimen of tenofovir-emtricitabine-efavirenz (TEE).","author":[{"propositions":[],"lastnames":["Zhao"],"firstnames":["Ying"],"suffixes":[]},{"propositions":[],"lastnames":["Keene"],"firstnames":["Claire","M"],"suffixes":[]},{"propositions":[],"lastnames":["Griesel"],"firstnames":["Rulan"],"suffixes":[]},{"propositions":[],"lastnames":["Sayed"],"firstnames":["Kaneez"],"suffixes":[]},{"propositions":[],"lastnames":["Gcwabe"],"firstnames":["Zimasa"],"suffixes":[]},{"propositions":[],"lastnames":["Jackson"],"firstnames":["Amanda"],"suffixes":[]},{"propositions":[],"lastnames":["Ngwenya"],"firstnames":["Olina"],"suffixes":[]},{"propositions":[],"lastnames":["Schutz"],"firstnames":["Charlotte"],"suffixes":[]},{"propositions":[],"lastnames":["Goliath"],"firstnames":["Rene"],"suffixes":[]},{"propositions":[],"lastnames":["Cassidy"],"firstnames":["Tali"],"suffixes":[]},{"propositions":[],"lastnames":["Goemaere"],"firstnames":["Eric"],"suffixes":[]},{"propositions":[],"lastnames":["Hill"],"firstnames":["Andrew"],"suffixes":[]},{"propositions":[],"lastnames":["Maartens"],"firstnames":["Gary"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme","A"],"suffixes":[]}],"doi":"10.12688/wellcomeopenres.16597.1","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhao et al. - 2021 - AntiRetroviral Therapy In Second-line investigating tenofovir-lamivudine-dolutegravir (ARTIST) protocol for a rando.pdf:pdf","issn":"2398-502X","journal":"Wellcome Open Research","keywords":"HIV,OA,Second-line,antiretroviral therapy,dolutegravir,fund_ack,protocol,randomised controlled trial","mendeley-tags":"OA,fund_ack,protocol","month":"feb","pages":"33","publisher":"F1000 Research Limited","title":"AntiRetroviral Therapy In Second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 1 approved]","url":"https://wellcomeopenresearch.org/articles/6-33/v1","volume":"6","year":"2021","bibtex":"@article{Zhao2021,\r\nabstract = {Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at least one fully active nucleoside reverse transcriptase inhibitor (NRTI). Resistance testing to select NRTIs is not feasible in low- and middle-income countries due to cost and limited laboratory capacity. Evidence suggests that recycling tenofovir plus lamivudine or emtricitabine backbone with dolutegravir could provide an effective second-line option. This study aims to determine the virologic efficacy of tenofovir-lamivudine-dolutegravir (TLD) with and without a lead-in supplementary dose of dolutegravir (to counteract the inducing effect of efavirenz) in patients failing a first-line regimen of tenofovir-emtricitabine-efavirenz (TEE).},\r\nauthor = {Zhao, Ying and Keene, Claire M and Griesel, Rulan and Sayed, Kaneez and Gcwabe, Zimasa and Jackson, Amanda and Ngwenya, Olina and Schutz, Charlotte and Goliath, Rene and Cassidy, Tali and Goemaere, Eric and Hill, Andrew and Maartens, Gary and Meintjes, Graeme A},\r\ndoi = {10.12688/wellcomeopenres.16597.1},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhao et al. - 2021 - AntiRetroviral Therapy In Second-line investigating tenofovir-lamivudine-dolutegravir (ARTIST) protocol for a rando.pdf:pdf},\r\nissn = {2398-502X},\r\njournal = {Wellcome Open Research},\r\nkeywords = {HIV,OA,Second-line,antiretroviral therapy,dolutegravir,fund{\\_}ack,protocol,randomised controlled trial},\r\nmendeley-tags = {OA,fund{\\_}ack,protocol},\r\nmonth = {feb},\r\npages = {33},\r\npublisher = {F1000 Research Limited},\r\ntitle = {{AntiRetroviral Therapy In Second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 1 approved]}},\r\nurl = {https://wellcomeopenresearch.org/articles/6-33/v1},\r\nvolume = {6},\r\nyear = {2021}\r\n}\r\n","author_short":["Zhao, Y.","Keene, C. M","Griesel, R.","Sayed, K.","Gcwabe, Z.","Jackson, A.","Ngwenya, O.","Schutz, C.","Goliath, R.","Cassidy, T.","Goemaere, E.","Hill, A.","Maartens, G.","Meintjes, G. A"],"key":"Zhao2021","id":"Zhao2021","bibbaseid":"zhao-keene-griesel-sayed-gcwabe-jackson-ngwenya-schutz-etal-antiretroviraltherapyinsecondlineinvestigatingtenofovirlamivudinedolutegravirartistprotocolforarandomisedcontrolledtrialversion1peerreview1approved-2021","role":"author","urls":{"Paper":"https://wellcomeopenresearch.org/articles/6-33/v1"},"keyword":["HIV","OA","Second-line","antiretroviral therapy","dolutegravir","fund_ack","protocol","randomised controlled trial"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["hiv","oa","second-line","antiretroviral therapy","dolutegravir","fund_ack","protocol","randomised controlled trial"],"search_terms":["antiretroviral","therapy","second","line","investigating","tenofovir","lamivudine","dolutegravir","artist","protocol","randomised","controlled","trial","version","peer","review","approved","zhao","keene","griesel","sayed","gcwabe","jackson","ngwenya","schutz","goliath","cassidy","goemaere","hill","maartens","meintjes"],"title":"AntiRetroviral Therapy In Second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 1 approved]","year":2021}